# ISCT 2015 Program

## Wednesday, May 27, 2015 Pre-Conference Day

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>0700 – 1900</td>
<td>Speaker Services</td>
<td>Genoa Room</td>
</tr>
<tr>
<td>0700 – 1900</td>
<td>REGISTRATION</td>
<td>Promenade Foyer</td>
</tr>
<tr>
<td>0800 – 1730</td>
<td>ISCT Global Regulatory Perspectives Workshop</td>
<td>Florentine Ballroom I/II</td>
</tr>
<tr>
<td>0800 – 1500</td>
<td>ISCT Flow Cytometry Workshop</td>
<td>Florentine Ballroom III/IV</td>
</tr>
<tr>
<td>0800 – 1700</td>
<td>ISCT Cord Blood Workshop (In partnership with the new Cord Blood Association)</td>
<td>Pompeian Ballroom III/IV</td>
</tr>
<tr>
<td>0800 – 1700</td>
<td>FACT Training Workshop</td>
<td>Pompeian Ballroom IV</td>
</tr>
<tr>
<td>0800 – 1500</td>
<td>FACT Training Breakout Session</td>
<td>Pompeian Ballroom III</td>
</tr>
<tr>
<td>1630 – 1830</td>
<td>Corporate Symposium – Miltenyi Biotec • See Corporate Guide for Details</td>
<td>Florentine Ballroom III/IV</td>
</tr>
<tr>
<td>1900 – 2130</td>
<td>EXHIBIT OPEN HOUSE AND WELCOME RECEPTION</td>
<td>Exhibit Hall – Palace Ballroom</td>
</tr>
</tbody>
</table>

## Thursday, May 28, 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>0700 – 1700</td>
<td>Speaker Services</td>
<td>Genoa Room</td>
</tr>
<tr>
<td>0700 – 1700</td>
<td>REGISTRATION</td>
<td>Promenade Foyer</td>
</tr>
<tr>
<td>0730 – 0900</td>
<td>STRATEGIES FOR COMMERCIALIZATION TRACK 1 – HOT TOPICS IN PROCESS AND PRODUCT DEVELOPMENT: PARTICULATES, SERUM–FREE MEDIA, AND BIOREACTORS</td>
<td>Pompeian Ballroom I/II</td>
</tr>
<tr>
<td>0730 – 0900</td>
<td>CHAIR: OHAD KARNIELI (IL)</td>
<td></td>
</tr>
<tr>
<td>0730 – 0900</td>
<td>PANELISTS: For Details on Discussion Breakdown see pg 46.</td>
<td></td>
</tr>
<tr>
<td>0730 – 0900</td>
<td>Harvey Brandwein (US), Shannon Eaker (US), Sarah Callens (UK), Thomas Brieva (US), Eytan Abraham (IL), Dominic Clarke (US), Jerry Martin (US), Vinod Vilivalam (US), Elizabeth J. Read (US), David Fiorentini (IL), Jessie Ni (US), Andrew Campbell (US), Christopher Bravery (UK), Steve Oh (SG)</td>
<td></td>
</tr>
<tr>
<td>0800 – 0900</td>
<td>TECHNICAL SESSION 1 – TECHNICAL ISSUES IN CORD BLOOD</td>
<td>Florentine Ballroom I/II</td>
</tr>
<tr>
<td>0800 – 0900</td>
<td>CHAIR: SUE ARMITAGE (US)</td>
<td></td>
</tr>
<tr>
<td>0800 – 0900</td>
<td>SPEAKERS:</td>
<td></td>
</tr>
<tr>
<td>0800 – 0900</td>
<td>Robin Smith Berger (US) – Cord Blood Collection 101</td>
<td></td>
</tr>
<tr>
<td>0800 – 0900</td>
<td>Sue Armitage (US) – How Can We Improve Cord Blood Collection Quality?</td>
<td></td>
</tr>
<tr>
<td>0800 – 0900</td>
<td>Karen Foster (US) – Cord Blood Collection Quality: Future Considerations</td>
<td></td>
</tr>
<tr>
<td>0800 – 0900</td>
<td>ISCT EARLY STAGE PROFESSIONALS GROUP #ISCT_ESP – CAREER OPTIONS FOR YOUNG PROFESSIONALS: WHY MY JOB ROCKS</td>
<td>Florentine Ballroom III/IV</td>
</tr>
<tr>
<td>0800 – 0900</td>
<td>CHAIR: DEBORAH GRIFFIN (US)</td>
<td></td>
</tr>
<tr>
<td>0800 – 0900</td>
<td>SPEAKERS:</td>
<td></td>
</tr>
<tr>
<td>0800 – 0900</td>
<td>Patrick Hanley (US) – ESP – The Academic Cell Therapy Laboratory Director</td>
<td></td>
</tr>
<tr>
<td>0800 – 0900</td>
<td>Emily Culme–Seymour (UK) – Career Options for ESPs: Leaving the Lab</td>
<td></td>
</tr>
<tr>
<td>0800 – 0900</td>
<td>Saar Gill (US) – Why My Job Rocks: Translational Research in Oncology</td>
<td></td>
</tr>
<tr>
<td>0800 – 0900</td>
<td>Tobi Fisher (US) – Physician Assistants: At the Forefront of Patient Care</td>
<td></td>
</tr>
</tbody>
</table>
Thursday, May 28, 2015

0800 – 0900  QUALITY AND OPERATIONS TRACK 1 – DESIGNING A GMP FACILITY
CHAIR: SHIRLEY BARTIDO (DE)

SPEAKERS:
Shirley Bartido (DE) – Design and Cost of an Academic GMP Facility
Carylynn Simmons (US) – Designing a cGMP Facility: Perspective of the Architect in the Development and Design of a cGMP Facility

Pompeian Ballroom III/IV

0900 – 0915  Opening Remarks

Roman Ballroom

0915 – 1045  PLENARY SESSION 1 – PRESIDENTIAL PLENARY: DISSECTING MSC HETEROGENEITY FROM UNEXPECTED ONTOGENY TO SPECIALIZED FUNCTIONS
CHAIR: MASSIMO DOMINICI (IT)

SPEAKERS:
Ivan Martin (CH) – Use of MSC to Engineer Developmental Processes for Regenerative Medicine
Simón Méndez–Ferrer (ES) – Bone Nature and Blood Nurture: Same Stroma?
Kaj Fried (SE) – Glial Cells of Peripheral Nerves Give Rise to Mesenchymal Stem Cells

Roman Ballroom
AMA PRA Category 1
Credits: 1.5

1045 – 1115  Coffee Break with Exhibits

Exhibit Hall - Palace Ballroom

1115 – 1230  ORAL PRESENTATION SESSION 1 – MSCS
CHAIR: LUC SENSEBÉ (FR)

PRESENTERS:
Olivia Candini (IT) – AGE RELATED miRNA SIGNATURE IN MESENCHYMAL PROGENITORS REVEALS KEY PLAYERS IN CELLULAR PERFORMANCE AND FATE
Yanling Liao (US) – RESCUE OF THE MUCOCUTANEOUS MANIFESTATIONS IN A MOUSE MODEL OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB) BY HUMAN CORD BLOOD DERIVED UNRESTRICTED SOMATIC STEM CELLS (USSCS)
Patrick Burger (NL) – FROM INDUCED PLURIPOTENT STEM CELLS TO MASSIVE ERYTHROID EXPANSION: A GLIMPSE INTO THE FUTURE OF TRANSFUSION MEDICINE
Yael Gothelf (IL) – NUROWN™: MESENCHYMAL STEM CELLS SECRETING NEUROTROPHIC FACTORS. AN AUTOLOGOUS CELL THERAPY IN CLINICAL TRIALS FOR ALS
Selim Kuci (DE) – COTRANSPLANTATION OF PREACTIVATED MESENCHYMAL Stromal CELLS WITH HEMATOPOIETIC STEM CELLS IMPROVES T–CELL REGENERATION

Florentine Ballroom I/II

1115 – 1230  ORAL PRESENTATION SESSION 2 – IMMUNOTHERAPY AND DENDRITIC CELL
CHAIR: BRUCE LEVINE (US)

PRESENTERS:
Yi Zhang (CN) – CLINICAL STUDY OF CYTOKINE–INDUCED KILLER CELLS–BASED IMMUNOTHERAPIES IN DIFFERENT STAGES OF RENAL CELL CARCINOMA
Barbara Withers (AU) – INFUSION OF THIRD–PARTY PARTIALLY HLA–MATCHED VIRUS–SPECIFIC T CELLS TO TREAT REFRACTORY VIRAL INFECTIONS
Arnaud Foussat (FR) – IMMUNOTHERAPY OF NON–INFECTIOUS UVEITIS USING ANTIGEN–SPECIFIC REGULATORY T (TREG) CELLS
Stefan Nierkens (NL) – PRECLINICAL DEVELOPMENT OF CORD BLOOD–DERIVED DENDRITIC CELL–BASED IMMUNOTHERAPIES AFTER HEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN WITH AML
Patrick Hanley (US) – CMVPP65–SPECIFIC T CELLS GENERATED FROM NAÏVE T CELL POPULATIONS RECOGNIZE ATYPICAL BUT NOT CANONICAL EPITOPES AND MAY BE PROTECTIVE IN VIVO

Florentine Ballroom III/IV
Thursday, May 28, 2015

ORAL PRESENTATION SESSION 3 – LEGAL AND ETHICAL & QUALITY AND OPERATIONS
CO–CHAIRS: DEBORAH GRIFFIN (US), THOMAS LEEMHUIS (US) AND MASSIMO DOMINICI (IT)

PRESENTERS:
- Rosario Isasi (CA) – THE ROLE OF CANADIAN CELL MANUFACTURING FACILITIES IN SHAPING THE REGULATORY AND COMMERCIALIZATION ENVIRONMENTS
- Aaron Levine (US) – CHALLENGES IN THE TRANSLATION AND COMMERCIALIZATION OF CELLULAR THERAPIES
- Philippe Willemse (BE) – SAFETY, EFFICACY AND QUALITY ASSESSMENT OF CELL THERAPEUTIC PRODUCTS THROUGHOUT MANUFACTURING CHANGES.
- John Fink (US) – PROTECTION OF INNOCENTS: CONTINUED SAMPLE WARM UP AFTER RETURN TO A CRYOGENIC ENVIRONMENT (BELOW –150°C) FOLLOWING A TRANSIENT AMBIENT PICKING OPERATION.
- Helene Rouard (FR) – THE FAILURE MODE, EFFECTS AND CRITICALITY ANALYSIS (FMECA) METHOD: A USEFUL APPROACH FOR RISK MANAGEMENT PLAN IN ADVANCED THERAPY MEDICINAL PRODUCTS MANUFACTURING.

STRATEGIES FOR COMMERCIALIZATION TRACK 2 – ANCILLARY MATERIALS
CO–CHAIRS: CLAUDIA ZYLBERBERG (US) AND LYNN CSONTOS (CA)

PANELISTS: Jennifer Solomon (CA), Joanne Kurtzberg (US), Jiwen Zhang (US), Brian Newsom (US)

ADVANCED PRACTICE PROFESSIONALS TRACK 1 – ADVANCES IN CELLULAR THERAPIES
CHAIR: TOBI FISHER (US)

SPEAKERS:
- Helen Heslop (US) – Novel T Cell Therapies on IND Studies
- Katy Rezvani (US) – Application of Natural Killer (NK) Immunotherapy in the Treatment of Cancer
- Bambi Grilley (US) – Novel T Cell Therapies

PLenary Session 2 – Cellular Immunotherapy
CHAIR: MALCOLM BRENNER (US)

SPEAKERS:
- Malcolm Brenner (US) – Adoptive Immunotherapy of Cancer Based on Virus–Specific T Cell
- Richard Childs (US) – Evaluation of Novel Pharmacologic and Genetic Approaches to Enhance Natural Killer Cell Cytotoxicity Against Cancer
- Richard Vile (US) – Combination of Immune Checkpoint Inhibition with Oncolytic Viroimmunotherapy
### Thursday, May 28, 2015

#### QUALITY AND OPERATIONS TRACK 2 – MAKING THE MOST OF AUDITS AND ENSURING DATABASE ACCURACY
**CO–CHAIRS: MICHELE SUGRUE (US) AND DEBORAH LAMONTAGNE (US)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1400</td>
<td>QUALITY AND OPERATIONS TRACK 2 – MAKING THE MOST OF AUDITS AND ENSURING DATABASE ACCURACY</td>
<td>Pompeian Ballroom III/IV</td>
</tr>
<tr>
<td>1400 – 1530</td>
<td>SPEAKERS:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Michele Sugrue (US) – Developing Audits Programs and Reports</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pamela Jacobson (US) – Successful Audit Strategies to Meet Accreditation Mandates and Avoid Citation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Debra Christianson (US) – Ensuring Database Accuracy: CIBMTR's Audit and Monitoring Program</td>
<td></td>
</tr>
</tbody>
</table>

#### ADVANCED PRACTICE PROFESSIONALS TRACK 2 – CHRONIC GVHD: REVISED SCORING, CASE PRESENTATIONS, ADVANCES IN TREATMENT
**CHAIR: KRISTEN KINDSVOGEL (US)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1530</td>
<td>ADVANCED PRACTICE PROFESSIONALS TRACK 2 – CHRONIC GVHD: REVISED SCORING, CASE PRESENTATIONS, ADVANCES IN TREATMENT</td>
<td>Capri Room</td>
</tr>
<tr>
<td>1530 – 1600</td>
<td>SPEAKER:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paul Carpenter (US) – Chronic GVHD: Revised Scoring, Case Presentations, Advances in Treatment</td>
<td></td>
</tr>
</tbody>
</table>

#### WORKSHOP 1 – IMMUNOTHERAPY COMBINATIONS: JOINT SESSION WITH SITC
**CO–CHAIRS: BRUCE LEVINE (US) AND HIDEHO OKADA (US)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1600</td>
<td>WORKSHOP 1 – IMMUNOTHERAPY COMBINATIONS: JOINT SESSION WITH SITC</td>
<td>Florentine Ballroom I/II</td>
</tr>
<tr>
<td>1600 – 1730</td>
<td>SPEAKERS:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zihai Li (US) – Taming Tregs for Adoptive T Cell Therapy of Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Muzaffar Qazilbash (US) – Idiotype–KLH Primed, Activated T Cells For Adoptive Cellular Therapy of Myeloma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hideho Okada (US) – Brain Tumor Cellular Therapy</td>
<td></td>
</tr>
</tbody>
</table>

#### WORKSHOP 2 – APPROACHES TO IMPROVE THE DEVELOPMENT OF CELL–BASED REGENERATIVE MEDICINE PRODUCTS VIA REGULATORY SCIENCE AND ADVOCACY
**CHAIR: MICHAEL MENDICINO (US)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1730</td>
<td>WORKSHOP 2 – APPROACHES TO IMPROVE THE DEVELOPMENT OF CELL–BASED REGENERATIVE MEDICINE PRODUCTS VIA REGULATORY SCIENCE AND ADVOCACY</td>
<td>Florentine Ballroom III/IV</td>
</tr>
<tr>
<td>1730 – 1830</td>
<td>SPEAKERS:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Michael Mendicino (US) – Cell–Based Regenerative Medicine Products for Clinical Trials – Regulatory Trends, Challenges and Opportunities</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Michael Werner (US) – The Alliance for Regenerative Medicine: Regulatory Strategies for Reform</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Steven Bauer (US) – Regulatory Science for Improved Characterization of Cell–Based Products: CBER’S MSC Consortium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anne Plant (US) – The Role of Measurements and Standards in a Regulated Environment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PANELIST: Natalie Mount (UK)</td>
<td></td>
</tr>
</tbody>
</table>

#### STRATEGIES FOR COMMERCIALIZATION TRACK 3 – POTENCY AND SAFETY ASSAY DEVELOPMENT
**CHAIR: CHRISTOPHER BRAVERY (UK)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1830</td>
<td>STRATEGIES FOR COMMERCIALIZATION TRACK 3 – POTENCY AND SAFETY ASSAY DEVELOPMENT</td>
<td>Pompeian Ballroom I/II</td>
</tr>
<tr>
<td>1830 – 1930</td>
<td>SPEAKERS:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Robert Perry (US) – Quality and Regulatory Considerations when Developing Potency Assays for Late Stage Cell Therapy Products</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Claudia Zylberberg (US) – Critical Considerations for the Development of Cell Therapy Potency Assays. Case Study: Angiogenesis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jon Rowley (US) – Assays for Developing Scalable, Cost Effective hMSC Manufacturing Processes</td>
<td></td>
</tr>
</tbody>
</table>
### Thursday, May 28, 2015

**1600 – 1730**

**QUALITY AND OPERATIONS TRACK 3 – COMMISSIONING AND VALIDATION OF A GMP FACILITY**

**CHAIR:** SHIRLEY BARTIDO (DE)

**SPEAKER:**

- **Mark Shannon (US)** – Clinical Manufacturing Facility Validation: “Keeping it Simple”

**ADVANCED PRACTICE PROFESSIONALS TRACK 3 – NERVOUS SYSTEM REPAIR/PULMONARY REGENERATION**

**CHAIR:** ALISON GULBIS (US)

**SPEAKERS:**

- **Daniel J. Weiss (US)** – Advances in Lung Regenerative Medicine
- **Joanne Kurtzberg (US)** – Game Changers: Using Cord Blood to Help the Brain

**1730 – 1900**

**Poster Session 1**

**1730 – 1900**

**GLOBAL TO LOCAL RECEPTION**

**1830 – 2030**

**ISCT EARLY STAGE PROFESSIONALS RECEPTION**

**Location TBA**

### Friday, May 29, 2015

**0730 – 1700**

**REGISTRATION**

**Promenade Foyer**

**0730 – 1700**

**TECHNICAL SESSION 2 – GETTING PERMISSION TO USE THE CLINIMACS CD34–SYTEM: HOW TO CONVINCE YOUR IRB IT’S NOT RESEARCH**

**CHAIR:** CAROLYN KEEVER–TAYLOR (US)

**SPEAKERS:**

- **Carolyn Keever–Taylor (US)** – HUD Approval and Approval for Non–Research Use
- **Ann LeFever (US)** – IRB Requirements To Obtain Permission Prior to the Purchase of the CliniMACS CD34–System as a HUD Usage
- **Joanne Kurtzberg (US)** – A Single Center Experience Obtaining Regulatory Approval for Use of the Clinimax After HUD Approval

**0800 – 0900**

**STRATEGIES FOR COMMERCIALIZATION TRACK 4 – REIMBURSEMENT**

**CHAIR:** RICHARD MAZIARZ (US)

**SPEAKERS:**

- **Stephanie Farnia (US)** – Reimbursement Challenges and Opportunities in Hematopoietic Cell Transplant: A Case Study
- **Panos Kefalas (UK)** – Regional Variations in Cell Therapy Reimbursement Across the Big5EU
- **Dawn Driscoll (US)** – Designing Cell Therapy Trials for Regulatory and HTA Approval

**0800 – 0900**

**QUALITY AND OPERATIONS TRACK 4 – VALIDATION BOOT CAMP PART I: CONCEPTS OF VALIDATION AND QUALIFICATION**

**CHAIR:** RENEE SMILEE (US)

**SPEAKERS:**

- **Lizette Caballero (US)** – Qualification, Validation and Verification: Say it Again?
Friday, May 29, 2015

PLENARY SESSION 3 – ADVANCED PHASE CLINICAL TRIAL UPDATES IN CELL BASED THERAPIES
CHAIR: ROBERT DEANS (US)

SPEAKERS:
- Robert Deans (US) – MultiStem®: Clinical Development Experience in Ischemic Injury and Inflammatory Disease
- Jeffrey Cohen (US) – Mesenchymal Stem Cell Transplantation to Treat Multiple Sclerosis

0915 – 1045

QUALITY AND OPERATIONS TRACK 5 – VALIDATION BOOT CAMP PART II: EQUIPMENT AND SUPPLIES
CHAIR: LYNN O’DONNELL (US)

SPEAKERS:
- Emily Hopewell (US) – Validation of an X–Ray Irradiator to Replace a Cesium Irradiator
- Ronit Slotky (US) – The Dextran Shortage – How to Approach the Validation of a New Critical Reagent
- Panel Members and Audience – Moving Your Facility – Qualification, Verification, Validation? All of the Above (And Then Some)

1045 – 1115

WORKSHOP 3 – STEM CELLS FOR NEUROLOGICAL DISORDERS
CHAIR: JOSEF PRILLER (DE)

SPEAKERS:
- Josef Priller (DE) – Stem Cells for Brain Repair
- Jan Nolta (US) – Mesenchymal Stem/Stromal Cells Engineered to Produce Brain–Derived Neurotrophic Factor as a Potential Treatment for Huntington’s Disease
- Chotima Bötcher (DE) – Hematopoietic Progenitors as a Tool to Treat Neurodegenerative Disorders?

1115 – 1230

ORAL PRESENTATION SESSION 4 – TRANSLATIONAL PROCESS DEVELOPMENT
CHAIR: OHAD KARNIELI (IL)

PRESENTERS:
- Ian Nicoud (US) – INTEGRATED AUTOMATION OF MULTIPLE UNIT OPERATIONS FOR PROCESSING AND EXPANDING CORD BLOOD HEMATOPOIETIC STEM AND PROGENITOR CELLS
- Raghavan Chinnadurai (US) – REPLICATIVE SENESCENCE ASSOCIATED IMPAIRMENT OF IMMUNOSUPPRESSIVE PROPERTIES OF MESENCHYMAL STROMAL CELLS
- Howard Kim (CA) – PROCESS DEVELOPMENT TOWARDS EFFICIENT LARGE–SCALE MANUFACTURING OF AN ALLOGENIC NATURAL KILLER CELL THERAPY
- Yanyan Han (CN) – A NOVEL CANCER IMMUNOTHERAPY WITH MULTIPLE TUMOR ANTIGEN ACTIVATED AUTOLOGOUS T CELLS FOR HEPATOCELLULAR CARCINOMA
### Friday, May 29, 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:15 – 12:30| **ORAL PRESENTATION SESSION 5 – CELL AND GENE THERAPY AND HEMATOPOIETIC STEM CELLS**  
**CO–CHAIRS: HELEN HESLOP (US) AND ELIZABETH J. SHPALL (US)**  
**PRESENTERS:**  
Kristen Fousek (US) – SAFETY OF MULTIPLE DOSES OF CAR T CELLS  
Bruce Levine (US) – CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS DIRECTED AGAINST CD19 (CTL019) INDUCE CLINICAL RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY CD19+ LYMPHOMAS  
Wael Abo Elkheir (EG) – COMBINED LOCAL MELANOCYTES AND SYSTEMIC MESENCHYMAL STEM CELL INJECTION IN VITILIGO TREATMENT  
Jiusheng Deng (US) – FUSOKINE GIFT4 TRIGGERS NOVEL B CELL FUNCTION ON HEMATOPOIETIC STEM CELLS  
Kevin Shoulars (US) – ALDEHYDE DEHYDROGENASE, BUT NOT VIABILITY OF CD34 CELLS, PREDICTS POTENCY AND ENGRAFTMENT AFTER CORD BLOOD TRANSPLANTATION |
| 12:30 – 14:00| Lunch with Exhibits  
Exhibit Hall - Palace Ballroom |
| 12:45 – 13:45| **ISCT PRESIDENTIAL TASK FORCE ON THE USE OF UNPROVEN CELLULAR THERAPIES ROUND TABLE: CONNECTING OUR STAKEHOLDERS, Communicating Knowledge, Translating the Proven**  
**CO–CHAIRS: MASSIMO DOMINICI (IT), KAREN NICHOLS (US), AARON LEVINE (US), AND JOHN RASKO (AU)**  
**Speakers: ISCT Presidential Task Force Members** |
| 12:45 – 13:45| **Corporate Tutorial – Fresenius Kabi • See Corporate Guide for Details**  
**Corporate Tutorial – Pall Life Sciences • See Corporate Guide for Details**  
**Corporate Tutorial – BioLife Solutions • See Corporate Guide for Details**  
**Corporate Tutorial – EMD Millipore • See Corporate Guide for Details** |
Friday, May 29, 2015

PLENARY SESSION 4 – GAME CHANGERS: POLICY AND PRACTICE CHANGES ENABLING THE COMMERCIALIZATION OF CELL AND TISSUE PRODUCTS
CHAIR: ABY J. MATHEW (US)

SPEAKERS:
- **Nick Crabb (UK)** – The Health Technology Assessment and Reimbursement of Cell Therapies
- **Reni Benjamin (US)** – Investing and Enabling the Cell Therapy Space: A Perspective from Wall Street

QUALITY AND OPERATIONS TRACK 7 – ENSURING QUALITY IN CELL BASED CLINICAL TRIALS
CHAIR: VIRAF VASANIA (IN)

SPEAKERS:
- **Viraf Vasania (IN)** – Ensuring Quality in Stem Cell–Based Products for Multi–Centric Clinical Trials
- **Stephen Minger (UK)** – Stem Cell Medicine– Its Potential and How to Ensure Quality in Multiple Trials Across Different Geographies
- **Sowmya Viswanathan (CA)** – Product Release Testing Considerations for Directed Allogeneic or Autologous Products
- **Aisha Khan (US)** – Clinical Trials: Moving Cell Based Therapies to the Clinic

WORKSHOP 4 – CELL BASED ASSAYS AS POTENCY RELEASE CRITERIA FOR MSC: JOINT SESSION WITH IFATS
CHAIR: LUC SENSEBÉ (FR)

SPEAKERS:
- **Christian Jorgensen (FR)** – MSC Based Therapy for Severe Osteoarthritis of the Knee: the ADIPOA Experience
- **Mauro Krampera (IT)** – Immunological Assays as Potency Release Criteria for Mesenchymal Stromal Cells (MSCs)
- **Jeffrey Gimble (US)** – Adipose Based Cell Assays

WORKSHOP 5 – ADVANCES IN CELL THERAPIES AND REGENERATIVE MEDICINE IN PULMONARY DISEASES AND CRITICAL ILLNESSES
CHAIR: DANIEL J. WEISS (US)

SPEAKERS:
- **Jennifer Wilson (US)** – Mesenchymal Stem Cells for the Treatment of ARDS: Results of a Phase 1 Clinical Trial
- **Daniel J. Weiss (US)** – It’s not Just MSCs: Other Adult Stem Cell Populations for Use in Cell Therapies for Lung Diseases and Critical Illnesses
- **Sarah Gilpin (US)** – Lung Bioengineering and Regeneration Based on Native Lung Scaffolds

STRATEGIES FOR COMMERCIALIZATION TRACK 6 – FINANCING AND INVESTMENT
CHAIR: RENI BENJAMIN (US)

SPEAKERS:
- **Reni Benjamin (US)** – The Declaration of Investment: Not All Cell Therapies are Created Equal
- **Joshua Schimmer (US)** – Investor’s Views of the Emerging GenomeRx Revolution
- **Jason Kolbert (US)** – Paradigms in Healthcare – Could the “Stem Cell Space” Be Next?
Friday, May 29, 2015

1600 – 1730
QUALITY AND OPERATIONS TRACK 8 – RATIONALE AND CHALLENGES OF BUILDING A GMP FACILITY IN ACADEMIA: A ROUND TABLE DISCUSSION
CHAIR: SHIRLEY BARTIDO (DE)

SPEAKERS:
Keith Thompson (UK) – Perspective on Cell Therapy Catapult Facility
Adrian Gee (US) – Perspective on Baylor College of Medicine Facility
Isabelle Rivière (US) – Perspective on Memorial Sloan Kettering Cancer Center Facility

1730 – 1900
Poster Session 2

1900 – Midnight
GALA DINNER • Ticketed Event - See Registration Desk For Details

Saturday, May 30, 2015

0730 – 1600
Speaker Services

0730 – 1500
REGISTRATION

0800 – 0900
TECHNICAL SESSION 3 – TECHNICAL TOOLS OF IMMUNOTHERAPY: EXPANSION OF NON–ANCHORED CELLS
CHAIR: PAUL ELDRIDGE (US)

SPEAKERS:
Natalia Lapteva (US) – Large Scale Manufacturing of Clinical–Grade Natural Killer Cells
Isabelle Rivière (US) – Engineering CAR–T cells for Cancer Immunotherapy
Tosten Tonn (DE) – Clinical Scale Isolation and Expansion of Untouched Antigen Specific T Cells

0915 – 1045
PLENARY SESSION 5 – TISSUE ENGINEERING
CHAIR: ALLAN DIETZ (US)

SPEAKERS:
Jeff Ross (US) – Advances in Natural Scaffolds to Grow Transplantable Organs
Scott Hollister (US) – 3D Printing for Patient Specific Implants and Regenerative Medicine
Utkan Demirci (US) – Advanced Technologies in Bioprinting and Biofabrication On–Chip Tissues Models

0915 – 1045
QUALITY AND OPERATIONS TRACK 9 – THE GOLDEN THREAD OF QUALITY
CO–CHAIRS: ALEX SLOBODIANSKI (DE) AND KARA WACKER (US)

SPEAKERS:
Alex Slobodianski (DE) – Quality Aspects of ATMP Development in Europe
Bangon (Day) Longsomboon (US) – Regulatory Expectations for Quality Management in the U.S.
Phyllis Warkentin (US) – Using the FACT Common Standards as a Stepping Stone
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1045 – 1115</td>
<td>Coffee Break with Exhibits</td>
<td>Exhibit Hall - Palace Ballroom</td>
</tr>
<tr>
<td>1115 – 1215</td>
<td>ORAL ABSTRACTS SESSION 6 – REGENERATIVE MEDICINE AND TISSUE ENGINEERING</td>
<td>Florentine Ballroom I/II</td>
</tr>
<tr>
<td></td>
<td>CHAIR: JACQUES GALIPEAU (US)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PRESENTERS:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Giles Kirby (AU) – DELIVERING A CELL THERAPY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Emily Culme–Seymour (UK) – COST OF STEM CELL-BASED TISSUE-ENGINEERED AIRWAY TRANSPLANTS IN THE UK: CASE SERIES</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chaolemeng Bao (SG) – PRE-TRANSPLANT OSTEOGENIC INDUCTION PROMOTES PRIMITIVE MESenchymAL STEM CELLS’ FUNCTIONAL SECRETION AND HEALING EFFICACY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Joseph Frank (US) – ENHANCED STEM CELL AND PROGENITOR CELL HOMING FOLLOWING IV INJECTION TO SKELETAL MUSCLE IN A MURINE MODEL OF MUSCULAR DYSTROPHY INDUCED BY PULSED FOCUSED ULTRASOUND (PFUS)</td>
<td></td>
</tr>
<tr>
<td>1115 – 1215</td>
<td>ORAL ABSTRACTS SESSION 7 – CARDIOVASCULAR REGENERATION AND NERVOUS SYSTEM REPAIR</td>
<td>Florentine Ballroom III/IV</td>
</tr>
<tr>
<td></td>
<td>CHAIR: JOSEF PRILLER (DE)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PRESENTERS:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Grace Asuelime (US) – PROCESS DEVELOPMENT OF THERAPEUTIC EXOSOME MANUFACTURING PROCESS TO CREATE A NON-LIVING REGENERATIVE MEDICINE PRODUCT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Shirley Mei (CA) – EFFICACY OF INTRAMUSCULAR ADMINISTRATION OF PLACENTA–DERIVED MESenchymAL–LIKE ADHERENT STROMAL CELLS (PLX–PAD) IN MONOCROTALINE–INDUCED PULMONARY ARTERIAL HYPERTENSION</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ruslan Semechkin (US) – HUMAN PARTHENOGENETIC DERIVED NEURAL STEM CELLS FOR THE TREATMENT OF PARKINSON’S DISEASE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Shibani Pati (US) – WNT3A RECAPITULATES THE NEUROPROTECTIVE EFFECTS OF MESenchymAL STEM CELLS AND PROMOTES NEUROCOGNITIVE RECOVERY IN TRAUMATIC BRAIN INJURY</td>
<td></td>
</tr>
<tr>
<td>1115 – 1215</td>
<td>QUALITY AND OPERATIONS TRACK 10 – TECHNOLOGY TRANSFER: ACADEMIA TO INDUSTRY (AND BACK AGAIN)</td>
<td>Pompeian Ballroom III/IV</td>
</tr>
<tr>
<td></td>
<td>CHAIR: MARK LOWDELL (UK)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SPEAKER:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moya Daniels (US) – Technological Development of a Cellular Therapeutic: Industry to Academia and Back Again</td>
<td>Pompeian Ballroom III/IV</td>
</tr>
<tr>
<td></td>
<td>Mark Lowdell (UK) – Moving a Trial from Academic GMP to CMO cGMP – a Real World Experience in Crossing the Atlantic</td>
<td>Pompeian Ballroom III/IV</td>
</tr>
<tr>
<td>1230 – 1340</td>
<td>ISCT ANNUAL GENERAL MEETING</td>
<td>Exhibit Hall - Palace Ballroom</td>
</tr>
<tr>
<td>1230 – 1345</td>
<td>CYTOTHERAPY: HOW TO REVIEW PAPERS FOR PEER-REVIEWED JOURNALS</td>
<td>Pompeian Ballroom I/II</td>
</tr>
<tr>
<td></td>
<td>CHAIR AND SPEAKER: JOHN BARRETT (US)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PRESENTER:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eduardo Almeida, Ph.D., NASA Research Scientist, Co-Director, Bone and Cell Signaling Laboratory, Space Biosciences Division, NASA Ames Research Center (US)</td>
<td>Roman Ballroom</td>
</tr>
</tbody>
</table>
Saturday, May 30, 2015

WORKSHOP 6 – IMMUNOMODULATION
CHAIR: YUFANG SHI (CN)

SPEAKERS:
- Yufang Shi (CN) – Stem Cells Immunology and Pathological and Therapeutic Implications
- Katarina Le Blanc (SE) – Bringing Mesenchymal Stem Cells into the Clinic
- Francesco Dazzi (UK) – Myeloid Precursors as Targets of Mesenchymal Stromal Cell Therapeutics

Florentine Ballroom I/II

STRATEGIES FOR COMMERCIALIZATION TRACK 8 – STEM CELL BIOPROCESSING/MANUFACTURING TECHNOLOGIES
CHAIR: KNUT NISS (US)

SPEAKERS:
- Anthony Davies (US)
- Steve Oh (SG)
  - Serum–Free Media Requirements Differ Greatly Between Monolayer and Microcarrier Cultures
- Sunil Mehta (US)
  - Overcoming Challenges of Volume Reduction and Cell Washing Process in Cell Therapy Manufacturing

Pompeian Ballroom I/II

QUALITY AND OPERATIONS TRACK 11 – STAFFING MODELS AND SUCCESSION PLANNING
CHAIR: KARL STASKO (US)

SPEAKERS:
- Sarah Nikiforow (US)
  - Challenges in Preparing Cellular Therapy Labs and Staffing for an Ever–Changing Future
- Suzanne Dworsky (US)
  - Staffing Models and Succession Planning for the Cell Therapy Laboratory
- Joseph Mierski (US)
  - Results from the ISCT Laboratory Practices Committee Cell Therapy Laboratory Staffing Survey

Pompeian Ballroom III/IV

1515 – 1530
Coffee Break
Exhibit Hall - Palace Ballroom

1530 – 1535
Announcement: Best Oral Abstract Award/Best Poster Award Recipients
Roman Ballroom

PLENARY SESSION 6 – NOT–FOR–PROFIT ORGANIZATIONS AND CONTRIBUTIONS TO ADVANCING CELL THERAPIES
CHAIR: C. RANDAL MILLS (US)

SPEAKERS:
- C. Randal Mills (US)
  - The California Institute for Regenerative Medicine
- Michael May (CA)
  - CCRM – Canada’s RM Commercialization Vehicle: Progress and Status after Four Years of Bridging the Gap
- Keith Thompson (UK)
  - Accelerating the Growth of the Industry by Supporting Commercialization

Roman Ballroom
AMA PRA Category 1 Credits: 1.5

QUALITY AND OPERATIONS TRACK 12 – TECHNICAL TOWN HALL MEETING: DISCUSSION OF COMMON OR EMERGING ISSUES FACING CELL THERAPY FACILITIES
CHAIR: VICKI ANTONENAS (AU)

PANELISTS: Paul Eldridge (US), Michael Watts (UK), Heather Daley (US), Renee Smilee (US)

Florentine Ballroom III/IV